biostudies-literatureUnknown13Campelo SN<h4>Background</h4>Irreversible electroporation (IRE) has been previously investigated in preclinical trials as a treatment for intracranial malignancies. Here, we investigate next generation high-frequency irreversible electroporation (H-FIRE), as both a monotherapy and a combinatorial therapy, for the treatment of malignant gliomas.<h4>Methods</h4>Hydrogel tissue scaffolds and numerical modeling were used to inform <i>in-vivo</i> H-FIRE pulsing parameters for our orthotopic tumor-bearing glioma model. Fischer rats were separated into five treatment cohorts including high-dose H-FIRE (1750V/cm), low-dose H-FIRE (600V/cm), combinatorial high-dose H-FIRE + liposomal doxorubicin, low-dose H-FIRE + liposomal doxorubicin, and standalone liposomal doxorubicin groups. Cohorts were compared againFrontiers in oncology1171278https://www.ebi.ac.uk/biostudies/studies/S-EPMC10196182biostudies-literatureHigh-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas.PMC10196182Garcia JThomas SCSaunier SVerbridge SSRossmeisl JHLorenzo MFPartridge BCampelo SNHinckley JAlinezhadbalalami NKani YDavalos RVfalseHigh-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas.<h4>Background</h4>Irreversible electroporation (IRE) has been previously investigated in preclinical trials as a treatment for intracranial malignancies. Here, we investigate next generation high-frequency irreversible electroporation (H-FIRE), as both a monotherapy and a combinatorial therapy, for the treatment of malignant gliomas.<h4>Methods</h4>Hydrogel tissue scaffolds and numerical modeling were used to inform <i>in-vivo</i> H-FIRE pulsing parameters for our orthotopic tumor-bearing glioma model. Fischer rats were separated into five treatment cohorts including high-dose H-FIRE (1750V/cm), low-dose H-FIRE (600V/cm), combinatorial high-dose H-FIRE + liposomal doxorubicin, low-dose H-FIRE + liposomal doxorubicin, and standalone liposomal doxorubicin groups. Cohorts were compared again2023-01-01T00:00:00Z20232025-04-26T21:25:44.165Z2025-04-06T16:50:19.241ZS-EPMC101961823721329810.3389/fonc.2023.1171278